Celularity Inc Ordinary Shares - Class A CELU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.77
- Day Range
- $0.75–0.84
- 52-Week Range
- $0.56–4.35
- Bid/Ask
- $0.76 / $0.77
- Shares Outstanding
- 28.95M
- Market Cap
- $22.59M
- Volume/Avg
- 16,925 / 154,444
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.75
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 115
- Website
- https://www.celularity.com
Valuation
|
Metric
|
CELU
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.75 |
Price/Cash Flow | — |
Price/Earnings
CELU
Financial Strength
|
Metric
|
CELU
|
|---|---|
Quick Ratio | 0.13 |
Current Ratio | 0.15 |
Interest Coverage | −12.62 |
Quick Ratio
CELU
Profitability
|
Metric
|
CELU
|
|---|---|
Return on Assets (Normalized) | −58.14% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −137.73% |
Return on Assets
CELU
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|r#x&T#% | LOCK|ppxR | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|fFPYfTK | LOCK|<N&b> | $71B | |||
| argenx SE ADR
ARGX
| LOCK|#d>GNrk | LOCK|pZ$ | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@Yfx%& | LOCK|>W# | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$jQpG@ | LOCK|<wsg | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$xKW>vF | LOCK|rMD! | $26B | |||
| Moderna Inc
MRNA
| LOCK|bk^@kY# | LOCK|^! | $25B | |||
| Incyte Corp
INCY
| LOCK|Lbl?Wws | LOCK|G# | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|@C$rN> | LOCK|rK | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|^Jph!d# | LOCK|&pb | $16B |
United States